East Ocyon Bio Pvt Ltd

Based in Gurgaon, India, and founded in 2022 by co-founders Dr. Dinesh Kundu (CEO), Dr. Renu Kundu, and Prof. Narinder Mehra, East Ocyon Bio Pvt Ltd operates as a provider of allogeneic CAR-NK cell therapies for cancer treatment to hospitals, clinics, and research organizations globally.

In December 2024, Easst Ocyon Bio Pvt Ltd raised USD 4. 2 million in seed funding co-led by Aeravti Ventures and Micro Labs Limited. East Ocyon Bio specializes in advanced cell therapy solutions, particularly focusing on the development of allogeneic chimeric antigen receptor (CAR)-natural killer (NK) cell therapies. These therapies utilize synthetic biology and non-viral cell engineering techniques to enhance the cancer-fighting capabilities of NK cells, positioning them as a transformative option for treating challenging cancers, including solid tumors.

The company's proprietary technology aims to streamline the production of these therapies, allowing for off-the-shelf solutions that can be readily accessed by patients, particularly in emerging markets such as India and other regions of the world. East Ocyon Bio’s client base includes healthcare providers and research institutions that seek advanced treatments for cancer, and its products are primarily targeted at patients requiring advanced therapeutic interventions across multiple geographical markets, including India, the United States, and Europe. East Ocyon Bio generates revenue through partnerships with healthcare providers and research institutions that utilize its CAR-NK cell therapy products. The company's transaction structure is primarily focused on B2B relationships, where it collaborates with hospitals and clinics for the deployment of its therapies in clinical settings.

East Ocyon Bio intends to expand its reach into international markets, targeting regions including the United States and Europe by 2025.